

# Press Release

## DICOT

### Dicot signs Agreement for Contract Research with Pelvipharm

**November 6, 2019, Uppsala, Sweden** – Dicot AB (publ) (“Dicot” or the “Company”) announced today that the company has entered into a research collaboration agreement with Pelvipharm, a world-leading contract research organization (CRO) based in France. This research collaboration is focused on the identification of Libiguin’s® mechanisms of action, which is a key step towards defining the exact domain for clinical use of the drug, and to support its registration as an approved drug.

Pelvipharm specializes in the field of male and female sexual dysfunctions, offering both *in vivo* and *in vitro* (i.e. "isolated organ") models for studying the physiological functions of the urogenital system and effects on drugs thereupon. This collaboration with Pelvipharm is a key part of Dicot's development of Libiguin® as we move towards registering the drug for the treatment of male sexual dysfunctions.

“We are very pleased that such a competent company as Pelvipharm now offers us the opportunity, in parallel with other ongoing research that Dicot is already conducting on understanding the mechanism of action of Libiguin®, to also be able to conduct studies with other batteries of models to obtain the knowledge we need about the effect of Libiguin® and its mechanism of action, concludes Göran Beijer.

The origin of Libiguin® stems from the research conducted at Uppsala University by Professor Jarl Wikberg on the root of a tree in Madagascar, which is used in folk medicine to treat sexual disability. Both, animal experimental studies conducted by Jarl Wikberg and the folk medical use of the roots indicate the potential of using Libiguin® for the treatment of erectile dysfunction and premature ejaculation in men.

**For further information, please contact:**

Julie Silber, CFO and Director of Investor Relations, Dicot

Tel: +46 79 348 62 77

E-mail: [julie.silber@dicot.se](mailto:julie.silber@dicot.se)

[www.dicot.se](http://www.dicot.se)

Rana Assaly, COO

Tel : +33 1 704 293 47

Email: [r.assaly@pelvipharm.com](mailto:r.assaly@pelvipharm.com)

[www.pelvipharm.com](http://www.pelvipharm.com)

This information is such that Dicot AB is required to make public in accordance with the EU’s Market Abuse Regulation (MAR). The information was made public by the Company’s contact person above on November 6, 2019.

**About Dicot AB**

Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The company's lead product, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 860 shareholders. For more information see [www.dicot.se](http://www.dicot.se).

### **About Pelvipharm**

Pelvipharm is a worldwide leading preclinical CRO delivering preclinical research services in urology and urogenital disorders (Benign Prostatic Hyperplasia, Overactive Bladder, Spinal Cord Injury, Painful bladder syndrome/Interstitial cystitis ...), male and female sexual dysfunctions (Erectile Dysfunction, Premature Ejaculation, Female Sexual Dysfunction including vaginal atrophy ...) and urogenital complications of cardiovascular / metabolism medicine and eating disorders (Hypertension, Atherosclerosis, Metabolic Syndrome, Diabetes,...) using a unique platform of both in vivo experimental models and in vitro animal and human tissue-based specific assays.